Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent | UniteRare Disease Library

Overview

Also known as:

Acute myeloid leukemia AML AML and myelodysplastic syndromes related to alkylating agent MDS Myelodysplastic syndromes

FDA & Trial Timeline

10 events

Dec 2027A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center — PHASE1, PHASE2

TrialNOT YET RECRUITING

Dec 2026FLT3-ITD Targeted Therapy in Fit AML Patients

European Organisation for Research and Treatment of Cancer - EORTC — PHASE2, PHASE3

TrialNOT YET RECRUITING

Oct 2026Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI) — PHASE2

TrialNOT YET RECRUITING

Aug 2026Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

M.D. Anderson Cancer Center — PHASE1

TrialNOT YET RECRUITING

May 2026High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Kittika Poonsombudlert — PHASE1

TrialNOT YET RECRUITING

May 2026Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS

University Hospital, Grenoble — NA

TrialNOT YET RECRUITING

Apr 2026Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

National Cancer Institute (NCI) — PHASE1, PHASE2

TrialRECRUITING

Apr 2026A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Takeda — PHASE3

TrialRECRUITING

Apr 2026A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

Aspera Biomedicines, Inc. — PHASE1

TrialNOT YET RECRUITING

Apr 2026Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML

Nationwide Children's Hospital — PHASE1, PHASE2

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →

Phase 38 trials

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Phase 3

Enrolling by Invitation

PI: Linghui Xia, Professor (Department of Hematology, Wuhan Union Hospital, To) · Sites: Wuhan, Hubei · Age: 18–99 yrs

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Phase 3

Actively Recruiting

PI: Study Director (Takeda) · Sites: Orange, California; Tamarac, Florida +144 more · Age: 18–99 yrs

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Phase 3

Actively Recruiting

· Sites: Denver, Colorado; Chicago, Illinois +60 more · Age: 18–99 yrs

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Phase 3

Actively Recruiting

PI: Gertjan Kaspers, Prof. Dr. (Pediatric Oncologist) · Sites: Utrecht, Utrecht · Age: 0–18 yrs

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

Phase 3

Active

PI: Jianxiang Wang, Dr (Institute of Hematology & Blood Diseases Hospital,) · Sites: Tianjin, Tianjin Municipality · Age: 14–55 yrs

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Phase 3

Active

PI: Charles Craddock (University of Birmingham) · Sites: Birmingham; Bristol +18 more · Age: 16–99 yrs

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Phase 3

Actively Recruiting

PI: Hartmut Doehner, MD (University of Ulm) · Sites: Innsbruck; Linz +89 more · Age: 18–75 yrs

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Phase 3

Active

· Sites: Louisville, Kentucky; Boston, Massachusetts +88 more · Age: 18–99 yrs

Phase 42 trials

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Phase 4

Actively Recruiting

· Sites: Orange, California; New York, New York · Age: 18–99 yrs

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

Phase 4

Actively Recruiting

· Sites: Hangzhou, Zhejiang · Age: 60–75 yrs

Other10 trials

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

Actively Recruiting

· Sites: Tianjin · Age: 14–99 yrs

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

Actively Recruiting

PI: Pierre PETERLIN, Dr (French Innovative Leukemia Organisation) · Sites: Amiens; Angers +19 more · Age: 18–99 yrs

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

Actively Recruiting

PI: Michael W Becker, MD (University of Rochester) · Sites: Rochester, New York · Age: 18–99 yrs

Registry of Patients Having Received oNKord®

Actively Recruiting

· Sites: Hanover; Basel · Age: 18–99 yrs

Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Actively Recruiting

· Sites: Burlington, Vermont · Age: 18–99 yrs

Muscle Dysfunction in Patients With Haematological Diseases

Active

· Sites: Copenhagen · Age: 18–99 yrs

A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

Active

PI: ABBVIE INC. (AbbVie) · Sites: Lecce, Apulia; Florence, Firenze +26 more · Age: 18–99 yrs

Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome

Actively Recruiting

· Sites: Beijing, Beijing Municipality · Age: 55–70 yrs

The Patient Cohort of the National Center for Precision Medicine in Leukemia

Actively Recruiting

· Sites: Bobigny; Paris +1 more

Institut Paoli Calmettes Myelodysplastic Syndromes Database

Actively Recruiting

PI: Norbert Vey, Pr (Institut Paoli-Calmettes) · Sites: Marseille, PACA · Age: 18–99 yrs

Specialists

Showing 25 of 240View all specialists →

He Huang

Specialist

Acute graft versus host disease Adult-onset myasthenia gravis Aplastic Anemia+8 more

PI on 11 active trials3 Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent publications

Overview

FDA & Trial Timeline

Treatments

Clinical Trials

Specialists

Treatment Centers

Travel Grants

Community

Latest news about Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Caregiver Resources

Common questions about Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent